PK-2

N/A

Report date: 2026/04/27 20:02:09

NME

Base Information

Drug NamePK-2

Drug Alias NameHPMA copolymer-doxorubicin conjugatesHPMA copolymer-Dox-galactosaminePK-2FCE-28069

ClassificationSmall molecules > Synthetic peptide > Peptide drug conjugate (PDC)

Mechanisms of ActionTopoisomerase II inhibitorsAsialoglycoprotein receptor binders

TargetsTopoisomerase IIAsialoglycoprotein receptor

Therapy Area/IndicationsLiver Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesPfizer Inc

China Registration ClassN/A

Active CompaniesN/A

Inactive CompaniesPfizer Inc

Active IndicationsN/A

Inactive IndicationsLiver Neoplasms

ATC CodeN/A